Key insights
- Agilent Technologies announced a strategic partnership with OpenAI and Boston Consulting Group to integrate AI across its products, operations, and customer workflows. This collaboration aims to enhance customer experience and product development, with plans for scaled deployment over the next 6-12 months. The news was met with a positive investor response, boosting Agilent's stock. This move signals a broader trend of established companies leveraging advanced AI for competitive advantage, potentially influencing other players in the healthcare technology and life sciences sectors.
SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE:A) announced Wednesday a collaboration with OpenAI and Boston Consulting Group to deploy artificial intelligence across its products, operations and customer workflows.
The partnership aims to integrate AI capabilities into Agilent’s instruments, software and services, according to a press release statement. Agilent has identified initial use cases focused on customer experience and its product pipeline, with plans to expand over the next six to 12 months.
"AI is a top priority, and this partnership reflects both our ambition and our execution commitment," said Padraig McDonnell, president and CEO of Agilent. "Our focus is simple: deliver faster, highest-quality insights to help our customers make better decisions."Investors responded positively to the announcement, with the stock posting a significant return over the last week, according to InvestingPro data. The company, valued at $38.1 billion, maintains a "GREAT" financial health score.
The collaboration combines Agilent’s scientific expertise and data with OpenAI’s AI research capabilities and BCG’s experience in large-scale transformation. The companies plan to identify, build and scale AI solutions across Agilent’s enterprise.
Ashley Kramer, vice president of Enterprise at OpenAI, said the partnership enables teams to unlock new insights and build more intelligent solutions. Matthew Kropp, managing director and senior partner at BCG and Chief AI Officer at BCG X, stated the collaboration will help Agilent move from pilots to scaled deployment.
Agilent generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. The company provides analytical and clinical laboratory technologies. With a gross profit margin of 53% and trading near its InvestingPro Fair Value, the stock is one of 1,400+ US equities covered by comprehensive Pro Research Reports.
The announcement did not disclose financial terms of the partnership or specific timelines for AI deployment beyond the six to 12-month expansion window.
In other recent news, Agilent Technologies Inc. announced that the U.S. Food and Drug Administration has approved the expanded use of its PD-L1 IHC 22C3 pharmDx diagnostic test for four additional cancer types. This approval allows the test to identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma for potential treatment with Merck’s KEYTRUDA. Additionally, Agilent’s second-quarter fiscal results exceeded expectations, with several analyst firms adjusting their outlooks based on the company’s performance. TD Cowen raised its price target for Agilent to $155, citing broad-based demand and the company’s Ignite initiative. RBC Capital also increased its price target to $155, noting strength in product cycles and positive momentum. Stifel reiterated a Buy rating with a $170 price target, highlighting the company’s strong quarterly results despite challenging macroeconomic conditions. Meanwhile, Wells Fargo lowered its price target to $160 due to valuation considerations but increased its earnings per share estimate for fiscal 2026. These developments reflect a mix of optimism and caution among analysts regarding Agilent’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.